In-depth Analysis and Data-driven Insights on the Impact of COVID-19 Included in this Global COVID-19 Diagnostics Market Report
The global COVID-19 diagnostics market by revenue is expected to register a negative CAGR of (9%) during the period 2021–2026.
The RT-PCR testing segment constituted over 75% of the global COVID diagnostics market share. The market is growing because of the outbreak of the coronavirus (SARS CoV-2) pandemic, which has increased the demand for rapid testing across the world. As the number of people suffering from the viral infection increases, the demand for rapid testing, which allows detecting the virus quickly, is growing. The adoption of a population-wide testing approach, which includes household, individual testing, is one of the trends influencing the demand for covid-19 diagnostics kits. The shift from symptomatic testing to mass testing in developed countries is another major factor affecting the market.
The following factors are likely to contribute to the growth of the COVID-19 diagnostics market during the forecast period:
• Increased Demand for Mass Testing
• Demand for Molecular Diagnostics due to Covid-19 Pandemic
• Unavailability of Specific Medicines/ Vaccines
The study considers the present scenario of the COVID-19 diagnostics market and its market dynamics for the period 2020?2026. It covers a detailed overview of several market growth enablers, restraints, and trends. The report offers both the demand and supply aspect of the market. It profiles and examines leading companies and other prominent ones operating in the market.
Global Covid-19 Diagnostics Market Segmentation This research report includes a detailed segmentation by product, end-users, test, technology, geography. In 2020, the consumables segment constituted over 74% of the global COVID-19 diagnostics market share. The demand for consumables, including biomarkers and reagents, including substrates, enzymes, electrolytes, specific proteins, lipids, and point-of-care test kits, is growing as they obtain quick and accurate results for diagnosing diseases, including COVID-19. The need to perform rapid testing to detect coronavirus spread across the world is driving the demand for consumables.
As RT-PCR testing is considered exceptionally reliable, the segment constituted over 75% of the global COVID diagnostics market share. The market is witnessing an increasing uptake of PCR testing to deliver a reliable diagnosis in quick succession. Currently, the reverse transcription-polymerase chain reaction (RT-PCR) is a standard for diagnosing COVID-19. With the WHO recommending PCR testing as one of the reliable methods for COVID-19 test procedures, countries such as the US, Brazil, Russia, India, Germany, Italy, and Spain drive the demand for PCR kits the virus highly infects these regions. Antigen and antibody testing accounted for a small share of the global COVID-19 diagnostics market. These tests are considered an important factor in mass screening. However, due to a lack of specificity and sensitivity, these tests were not initially used in several countries. As the COVID-19 pandemic continues, vendors came up with advanced antibody and antigen tests, driving the market growth.
The failure of several rapid diagnostics kits to detect the presence of the COVID-19 virus in several countries has led to the development of molecular-based-PCR testing for covid-19 diagnosis. The share of molecular diagnostic test makers has increased drastically, with the WHO declaring RT-PCR as the standard test for Covid-19 diagnosis. This trend is followed in several developed, developing, and underdeveloped countries, thereby generating a high demand for molecular diagnostic testing. The immunoassay segment accounted for over 24% of the global market share in 2020. These tests are conducted on those with maximum exposure to the covid-19 virus, especially healthcare professionals and medical practitioners.
In most countries, diagnostic laboratories, which include standard and public health laboratories, have played a significant role in detecting covid-19. The demand for standalone laboratories is growing gradually owing to the prevalence of pandemic, epidemic conditions, or the outbreak of unexpected infectious diseases, requiring immediate diagnosis of the diseases for a large population in a shorter time. Hospitals have played a major role in covid-19 testing since its outbreak. A majority of hospitals have their own in-house laboratories to conduct diagnostic tests, which help them to admit and monitor COVID-19 patients. Hence the segment is witnessing a high demand for COVID-19 testing kits. The demand for COVID-19 diagnostic kits from ambulatory care settings increased in developed countries as these settings accommodated several asymptomatic patients.
By Product
• Consumables
• Analyzers/Instruments
By Test
• PCR
• Antigen
• Antibody
By Technology
• Molecular
• Immunology
By End-user
• Laboratories
• Hospitals
• Ambulatory Care Settings
• Research Institutes
INSIGHTS BY GEOGRAPHY APAC emerged as the largest Covid-19 diagnostics market and is likely to retain its position during the forecast year due to the widespread COVID infection in the population. Several countries in the region, especially India, where the number of people infected with coronavirus stood at 8.5 million in October 2020, are likely to increase mass testing, thereby increasing the demand. The presence of a large population, poor living standards, and inadequate medical infrastructure are the major factors responsible for the infection’s high prevalence. However, increased mass testing initiatives and high investments in public healthcare services are likely to favor the COVID-19 diagnostics testing market. China, Japan, India, South Korea, and Australia are the major revenue contributors to the APAC COVID-19 diagnostics market. Several countries preferred using PCR-based testing due to their higher accuracy than serological tests. Australia and New Zealand have increased their testing capacities to reduce the impact of the disease.
By Geography
• North America
o US
o Canada
• Europe
o UK
o Germany
o France
o Italy
o Spain
o Russia
• APAC
o China
o Japan
o South Korea
o Australia
o India
o Indonesia
o Philippines
• Latin America
o Brazil
o Mexico
o Argentina
o Peru
o Colombia
o Chile
• Middle East & Africa
o Saudi Arabia
o South Africa
o Turkey
o Iran
INSIGHTS BY VENDORS The global coronavirus diagnostics market is highly dynamic with the presence of several global, regional, and local company profiles, offering a diverse range of analyzers, test kits, assays, and reagents to perform COVID-19 tests. Abbott, BD, Danaher, F. Hoffmann-La Roche, Siemens Healthineers, and Thermo Fisher Scientific are the major player in the diagnostics market. Global market players focus on developing innovative products and expanding their product portfolio to remain competitive in the market. They are investing extensively in R&D and product development activities to expand their product portfolio.
KEY QUESTIONS ANSWERED 1. What is the total market value of the COVID-19 Diagnostics Market report?
2. Which test type accounted for the largest COVID-19 diagnostics market share?
3. Will COVID-19 testing demand drive the global point-of-care testing market?
4. What factors could help to bridge the supply-chain gap in the market?
5. Which are the key perspectives that key vendors are leveraging to move businesses to a new growth trajectory?
6. What are some of the potential barriers for the existing players in the market?
Our reports have been used by over 10K customers, including:
The Asia Pacific organoids market is expected to reach US$ 513.74 million in 2027 from US$ 97.02 million in 2019. The market is estimated to grow at a CAGR of 23.1% from 2020 to 2027. Rising adoption of biobanking and tumor modelling and alternatives for animal testing models acting as kingpins are expected to augment the growth of the...
The Europe organoids market is projected to reach US$ 1,260.08 million by 2027 from US$ 247.85 million in 2019; it is estimated to grow at a CAGR of 22.5% from 2020 to 2027. Increasing demand for tumor modelling and biobanking and rising adoption of personalized drugs are expected to drive the market. Personalized medicine is a growing...
The Middle East & Africa organoids market is expected to reach US$ 141.26 million in 2027 from US$ 37.34 million in 2019; the market is estimated to grow at a CAGR of 20.9% from 2020 to 2027. The growth of the market can be attributed to growing research on organoids in the Middle East & Africa region and rising focus on developing alternatives...
The global organoids market is expected to reach US$ 3,420.40 million by 2027 from US$ 689.47 million in 2019. The market is estimated to grow at a CAGR of 22.1% from 2020 to 2027. Increasing demand for tumor modelling and biobanking, rising adoption of personalized drugs, and growing focus on developing alternatives for animal testing...
The global immunofluorescence assays market is projected to reach USD 3.5 billion by 2026 from USD 2.6 billion in 2021, at a CAGR of 6.0% during the forecast period. The growth in this market is primarily attributed to the increasing prevalence of chronic diseases and rising R&D spending & healthcare expenditure. Emerging markets are expected...
The global human microbiome market is expected to reach US$ 1,873.53 million by 2027 from US$ 356.29 million in 2019. The market is estimated to grow with a CAGR of 23.6% from 2020 to 2027. The growth of the market is driven by the factors such as increasing incidence of lifestyle diseases, increasing focus on human microbiome therapies,...
An organ-on-a-chip is a microfluidic cell culture device that contains continuously perfused chambers. This chip develops a narrow channel for the blood and airflow in organs, such as the lung, gut, liver, heart, and other organs. Such devices produce multiple levels of tissue and organ functionalities, which are not feasible using conventional...
Healthy future: Despite the mounting likelihood of new regulation, industry revenue will likely grow Abstract Cryogenic Biobanking Services Since the landmark scientific achievement of human genome sequencing in 2003, the Cryogenic Biobanking Services industry is increasingly viewed as the link between...
17 pages •
By Euromonitor International
• Feb 2021
Natural increase will be the sole driver of swift population growth in Pakistan in 2020-2040, as net migration remains negative. Ageing will be quite slow over this timeframe, with the country remaining extremely young in a regional context due to relatively elevated birth rates and low life expectancy. Urbanisation will be swift and the country...
17 pages •
By Euromonitor International
• Feb 2021
Natural increase will be the main driver of population expansion in the United Arab Emirates in 2020-2040. Net migration rates will be negative or low up to 2040, though reliance on foreign labour means foreign citizens will continue to account for over 86% of the population. Ageing and a fall in working age population will alter population...
Healthcare
Diabetes
Obesity
Pathology
Chronic Disease
United Arab Emirates
World
Life Expectancy
Net Migration Rate
By continuing to use this site you consent to the use of cookies on your device as described in our Cookie Policy unless you have disabled them.
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.
